The finale weighs whether GLP-1 drugs are a wonder drug or a very good drug dressed as one. It sets root-cause optimists against disciplined skeptics and systems thinkers who say adoption has outrun clinical trials, then offers an evenhanded way to judge the next headline.
Who's who
- Richard DiMarchiIndiana University chemist and co-inventor of tirzepatide; voice of the root-cause optimists
- Daniel Drucker+2 more episodesToronto scientist and founding GLP-1 figure; believer who refuses to oversell
- Randy SeeleyUniversity of Michigan obesity researcher arguing adoption has outrun the trial machine
- Julia BelluzJournalist whose 2026 New York Times Opinion piece framed a "great experiment"
Still debated
How much benefit is independent of weight, and whether inflammation is the unifying mechanism, remain unsettled. Long-term safety in healthy users, the value of real-world data in place of trials, and why the brain trials failed are also open.
